Publication of research by the Robert Koch Institute in the field of antiretrovirals (Cost savings and potential savings through the distribution of generic antiretroviral drugs on the statutory health insurance market in Germany between …): Drugs and therapies – Antiretrovirals


FEBRUARY 01, 2022 (NewsRx) — By a News Reporter – Staff News Editor at Daily Insurance News — New data on antiretrovirals are presented in a new report. According to reports from the Robert Koch Institute by the editors of NewsRx, the research said, “Recent patent losses for antiretroviral (ARV) drugs have led to the debate about cutting costs through replacing patented drugs with generic drugs. The separation of recommended single-pill (STR) regimens into their single-substance partners is one of the considerations mentioned in said debate.

Financial support for this research includes Robert Koch Institute Award:.

Journalists got a citation from the research of Robert Koch Institute“In particular, the generic tenofovir disoproxil/emtricitabine (TDF/FTC) is expected to hold untapped savings potential, which could curb the increase in overall spending on combination antiretroviral therapy (cART) under the Statutory Health Insurance (SHI) of Germany. Data on ARVs reimbursed by the SHI were used to describe trends in defined daily doses (DDD) as well as income in the German ARV market. They were also used to determine the cost savings associated with switching to generic drugs. The period observed was between January 2017 and June 2019. Potential savings were determined considering the following assumptions: the maximum possible use of generic ARVs, including 1) splitting the STR and replacing all substance partners with generics, and 2) replacing the tenofovir alafenamide/emtricitabine (TAF/FTC) with TDF/genericFTC. Throughout the observation period, the DDD of generic ARVs increased almost fivefold while their revenues more than quadrupled. Total cost savings increased significantly over the same period, with generic TDF/FTC representing a share of approximately 70%. The greatest potential saving could have been achieved by replacing the TAF/FTC with generic TDF/FTCpeaking at nearly 10% of total revenue, but showing declining trends overall. »

According to the reporters, the research concluded: “Phasing out generic ARVs ensured increasing savings, but consequently dampened potential savings. Generic TDF one-time price reductions/FTC played a central role in these effects. In any case, switching to generic ARVs should not fail to adhere to treatment guidelines and continue to consider medical requirements for treatment.

For more information on this research, see: Cost savings and potential savings through the distribution of generic antiretroviral drugs in the statutory health insurance market of Germany between January 2017 and June 2019. BMC Health Services Research, 2022.22(1):1-9. (BMC Health Services Research – The editor for BMC Health Services Research is BMC.


A free version of this review article is available at

Our editors advise that additional information can be obtained by contacting Matthaus Lottes, Department of Methodology and Research InfrastructureManagement of information and research data, Robert Koch Institute. Other authors of this research include Viviane Bremer, Christof PruggerChristian Kollan, Daniel Schmitt.

(Our reports provide factual information on research and discoveries from around the world.)


Comments are closed.